<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679508</url>
  </required_header>
  <id_info>
    <org_study_id>Vonoprazan-4003</org_study_id>
    <secondary_id>U1111-1178-8948</secondary_id>
    <secondary_id>JapicCTI-163153</secondary_id>
    <nct_id>NCT02679508</nct_id>
  </id_info>
  <brief_title>Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety</brief_title>
  <official_title>Vonoprazan Study In Patients With Erosive Esophagitis to Evaluate Long-term Safety: A Study to Evaluate the Safety of Long-term Administration of Vonoprazan in Maintenance Treatment in Patients With Erosive Esophagitis (EE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is exploratorily evaluate the effect on gastric mucosal tissue and
      the safety of long-term administration (260 weeks: 5 years) of vonoprazan 10 mg or 20 mg in
      patients receiving maintenance treatment after healed erosive esophagitis (EE), and the
      curative effect of vonoprazan 20 mg versus lansoprazole in patients with EE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label, randomized, parallel-group study to exploratorily evaluate
      the effect on gastric mucosal tissue and the safety of long-term administration of vonoprazan
      in maintenance treatment after healed EE, and the curative effect of vonoprazan versus
      lansoprazole in participants with EE.

      Participants endoscopically diagnosed with EE of Los Angeles (LA) Classification Grades A to
      D at the start of treatment (Week 0 of the healing phase) will be randomly assigned to
      receive either vonoprazan 20 mg or lansoprazole 30 mg to be taken once daily for up to 8
      weeks. Subjects with healed EE as confirmed endoscopically at Week 4 or 8 in the healing
      phase will enter the maintenance phase.

      In the maintenance phase, the vonoprazan group and the lansoprazole group will be
      administered a starting dose of 10 mg and 15 mg, respectively, once daily up to 260 weeks.

      If the principal investigator or investigator judged the effect of vonoprazan 10 mg or
      lansoprazole 15 mg to be insufficient as the maintenance treatment of EE, vonoprazan and
      lansoprazole may be increased to 20 mg and 30 mg, respectively.

      The research period will consist of two subperiods: healing phase in which participants with
      EE will receive treatment (for 4 or 8 weeks) and maintenance phase in which participants will
      receive maintenance treatment (for 260 weeks), and thus, a total of up to 268 weeks. The
      number of visits will be a maximum of 18 visits. Planned number of research subjects, as the
      number of research subjects for entry to the maintenance phase, will be 130 participants in
      the vonoprazan group and 65 participants in the lansoprazole group.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 29, 2016</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with clinically significant Gastric mucosa histopathology findings</measure>
    <time_frame>Up to Week 268</time_frame>
    <description>For each gastric mucosa histopathological endpoint (presence or absence of malignant alteration of epithelial cells, presence or absence of prominence/hyperplasia of wall cells, presence or absence of hyperplasia of crypt epithelial cells, presence or absence of proliferation of endocrine cells, and presence or absence of hyperplasia of G cells), the proportion of research participants who have the events for assessment in maintenance phase shall be calculated for each treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic erosive esophagitis (EE) recurrence rate</measure>
    <time_frame>Up to Week 268</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EE healing rate at the end of the healing phase</measure>
    <time_frame>Up to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting One or More Treatment-emergent Adverse Events</measure>
    <time_frame>Up to Week 268</time_frame>
    <description>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinically significant endoscopic findings</measure>
    <time_frame>Up to Week 268</time_frame>
    <description>For each endoscopic endpoint (presence or absence of fundic gland polyp, presence or absence of hyperplastic polyp, presence or absence of cobblestone mucosa, presence or absence of multiple white flat elevation, and presence or absence of black spots), the proportion of research participants who have the clinically significant events at each time point for assessment shall be calculated for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinically significant histological evaluation of gastritis according to the Sydney classification</measure>
    <time_frame>Up to Week 268</time_frame>
    <description>For each histological endpoint of gastritis according to the Sydney classification [inflammation (mononuclear infiltration), activity (neutrophilic infiltration), atrophy, intestinal metaplasia, and H. pylori], the proportion of research participants who have the clinically significant events at each time point for assessment shall be calculated for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who have gastric polyp in maintenance phase</measure>
    <time_frame>Up to Week 268</time_frame>
    <description>For gastric polyp, the proportion of research participants who have gastric polyp in maintenance phase of this study shall be calculated for each treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>Vonoprazan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan</intervention_name>
    <description>Vonoprazan fumarate 10 mg or 20 mg capsules</description>
    <arm_group_label>Vonoprazan group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole 15 mg or 30 mg capsules</description>
    <arm_group_label>Lansoprazole group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Healing Phase:

          1. Participants endoscopically diagnosed with EE of grades A to D by the LA
             Classification Grading System at the start of treatment (Week 0 of the healing phase)

          2. Participants with H. pylori negative

          3. Participants who, in the opinion of the principal investigator or investigator, are
             capable of understanding the content of the clinical research and complying with the
             research protocol requirements.

          4. Participants who can sign and date an informed consent form and information sheet
             prior to the conduction of the clinical research procedures.

          5. Male or female participants aged 20 years or older at the time of informed consent

          6. Therapeutic category: Ambulatory

             Maintenance Phase:

          7. Participants who have endoscopically confirmed EE healing* (mucous membrane disorder
             is not observed) at completion of the healing phase (Week 4 or 8 of the healing phase)

             * Participants who are classified as grade 0 according to severity classification of
             EE (See Table 9.b)

          8. Participants who have been determined to be appropriate as subjects for maintenance
             treatment of EE by the principal investigator or investigator

        Exclusion Criteria:

        Healing Phase:

          1. Participants with concurrent peptic ulcer (except scarred stage) or Zollinger-Ellison
             syndrome

          2. Participants who received treatment with PPIs (including vonoprazan) within 4 weeks
             (Week -4 to Week 0) prior to the start of healing phase (Week 0 of the healing phase)

          3. Participants with a history of H. pylori eradication.

          4. Participants who have received surgery or treatment affecting gastroesophageal reflux
             (fundoplication or dilation for esophageal stenosis [excluding Schatzki's ring], etc.)

          5. Participants with an esophagus-related complication (eosinophilic esophagitis,
             esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis,
             etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or
             physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with
             Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or
             Barrett's esophagus are allowed to be included.

          6. Participants with clinically apparent hepatic impairment (e.g., AST or ALT levels at
             the time of informed consent: &gt;1.5 times the upper limit of normal (ULN).

          7. Participants with renal impairment or renal failure [creatinine clearance (CCr) Ë‚30
             mL/min, etc.]

          8. Participants with a history of hypersensitivity or allergy for PPIs.

          9. Participants with a history of gastrectomy, gastrointestinal resection, or vagotomy

         10. Participants with a malignant tumor

         11. Participants who are pregnant, breast-feeding, possibly pregnant, or planning to
             become pregnant

         12. Participants with one of the diseases listed under administration contraindication in
             the vonoprazan or lansoprazole package insert

         13. Participants planning to take prohibited concomitant medications during the research
             period

         14. Participants participating in other clinical studies

         15. Participants who have been determined to be inappropriate as subjects in the study by
             the principal investigator or investigator

             Maintenance Phase:

         16. Participants who have taken PPIs other than the study drug or the control drug during
             the healing phase

         17. Participants who have been determined to be inappropriate as subjects in the study by
             the principal investigator or investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Pharmaceuticals Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Abiko</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ichikawa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kama</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hakodate</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fushimi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yufu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ohtsu</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izunokuni</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaizu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ohtawara</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophagitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

